AFRICANGLOBE – This is a call for an immediate, thorough, and independent investigation of Tulane University researchers (see here and here) and their Fort Detrick associates in the US biowarfare research community, who have been operating in West Africa during the past several years.
What exactly have they been doing?
Exactly what diagnostic tests have they been performing on citizens of Sierra Leone?
Why do we have reports that the government of Sierra Leone has recently told Tulane researchers to stop this testing?
Have Tulane researchers and their associates attempted any experimental treatments (e.g., injecting monoclonal antibodies) using citizens of the region? If so, what adverse events have occurred?
The research program, occurring in Sierra Leone, the Republic of Guinea, and Liberia—said to be the epicenter of the 2014 Ebola outbreak—has the announced purpose, among others, of detecting the future use of fever-viruses as bioweapons.
Is this purely defensive research? Or as we have seen in the past, is this research being covertly used to develop offensive bioweapons?
For the last several years, researchers from Tulane University have been active in the African areas where Ebola is said to have broken out in 2014.
These researchers are working with other institutions, one of which is USAMRIID, the US Army Medical Research Institute of Infectious Diseases, a well-known center for biowar research, located at Fort Detrick, Maryland.
In Sierra Leone, the Tulane group has been researching new diagnostic tests for hemorrhagic fevers.
Note: Lassa Fever, Ebola, and other labels are applied to a spectrum of illness that result in hemorrhaging.
Tulane researchers have also been investigating the use of monoclonal antibodies as a treatment for these fevers—but not on-site in Africa, according to Tulane press releases.
Here are excerpts from supporting documents.
Tulane University, Oct. 12, 2012, “Dean’s Update: Update on Lassa Fever Research”
“In 2009, researchers received a five-year $7,073,538 grant from the National Institute of Health to fund the continued development of detection kits for Lassa viral hemorrhagic fever.
“Since that time, much has been done to study the disease. Dr. Robert Garry, Professor of Microbiology and Immunology, and Dr. James Robinson, Professor of Pediatrics, have been involved in the research of Lassa fever. Together the two have recently been able to create what are called human monoclonal antibodies. After isolating the B-cells from patients that have survived the disease, they have utilized molecular cloning methods to isolate the antibodies and reproduce them in the laboratory. These antibodies have been tested on guinea pigs at The University of Texas Medical Branch in Galveston and shown to help prevent them from dying of Lassa fever.
“Most recently, a new Lassa fever ward is being constructed in Sierra Leone at the Kenema Government Hospital. When finished, it will be better equipped to assist patients affected by the disease and will hopefully help to end the spread of it.” [The Kenema Hospital is one of the centers of the Ebola outbreak.]